Elite Journal of HIV. Volume 2 issue 1(2024), Pp. 65-78
https://epjournals.com/journals/EJHIV

Managing Hematological Complications in HIV: Erythropoietin Considerations

*Emmanuel Ifeanyi Obeagu[1], Arinze Favour Anyiam [2] and Getrude Uzoma Obeagu[3]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
[2]Department of Medical Laboratory Science, School of Basic Medical and Health Sciences, Igbinedion University, Okada, Edo State, Nigeria.
School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

Hematological complications, prominently anemia, pose a multifaceted challenge in the healthcare landscape for individuals living with Human Immunodeficiency Virus (HIV). This critical review critically examines the complexities of managing hematological complications in the context of HIV, with a particular emphasis on the considerations and potential benefits of erythropoietin (EPO) therapy. The prevalence and etiology of anemia in HIV, along with the underlying mechanisms contributing to its development, are explored to provide a comprehensive understanding of the hematological challenges faced by this population. The review delves into the physiological role of EPO, assessing its potential as a therapeutic intervention for anemia in HIV, while scrutinizing the associated risks and benefits. Optimal dosing strategies, individualized approaches, and the clinical outcomes associated with EPO therapy are critically evaluated. Through synthesizing current knowledge and addressing research gaps, this review aims to contribute to the enhancement of holistic care for individuals grappling with hematological complications in the intricate milieu of HIV.

Keywords*: HIV, Anemia, Hematological Complications, Erythropoietin, EPO Therapy, Mechanisms, Risks, Benefits.*

Introduction

Human Immunodeficiency Virus (HIV) infection is characterized by its diverse impact on various physiological systems, including the hematological system, where complications such as anemia significantly contribute to the overall burden of disease. Hematological complications, particularly anemia, are prevalent among individuals living with HIV and pose unique challenges to patient care.[1-15] The association between HIV and hematological abnormalities, such as anemia, is well-

established. Studies indicate a high prevalence of anemia in individuals living with HIV, manifesting at various stages of the disease. The etiology of anemia in this population is multifactorial, involving direct viral effects, opportunistic infections, medication side effects, and chronic inflammation.[16-25] Hematological complications, especially anemia, not only contribute to diminished quality of life but also have implications for the overall management of HIV. Anemia can exacerbate the effects of immunosuppression, compromise oxygen delivery to tissues, and potentially impact disease progression.[26-31] Erythropoietin, a glycoprotein hormone primarily produced in the kidneys, plays a pivotal role in the regulation of erythropoiesis. EPO therapy has emerged as a promising avenue for managing anemia in various clinical settings, including HIV.

Physiological Role of Erythropoietin

Erythropoietin (EPO) is a crucial glycoprotein hormone that plays a central role in the regulation of erythropoiesis, the process by which red blood cells (RBCs) are produced. Produced primarily in the kidneys, EPO serves as a key mediator in maintaining the balance of oxygen delivery to tissues and organs. EPO is primarily synthesized and released by specialized cells in the kidneys, specifically in the renal interstitial fibroblasts. The production of EPO is tightly regulated by the oxygen status of tissues. In response to hypoxia, or low oxygen levels in the blood, the kidneys release more EPO. This process is mediated by the hypoxia-inducible factor (HIF) pathway, where low oxygen levels stabilize HIF, leading to increased EPO gene transcription and subsequent release.[32-36] The primary target tissues for EPO are the bone marrow, specifically the hematopoietic stem cells and erythroid progenitor cells. EPO exerts its effects by binding to specific receptors, namely the EPO receptor (EPOR), which are present on the surface of these cells. The interaction between EPO and its receptor triggers a cascade of intracellular signaling events that ultimately influence the survival, proliferation, and differentiation of erythroid progenitor cells.[37-42] The central role of EPO is to stimulate erythropoiesis, the process of red blood cell formation. By binding to EPOR on hematopoietic stem cells and committed erythroid progenitors, EPO promotes their differentiation into mature red blood cells. This involves the regulation of various genes controlling cell cycle progression, survival, and hemoglobin synthesis. The net effect is an increased production of red blood cells to meet the body's demand for oxygen transport.[43]

EPO's responsiveness to hypoxia positions it as a key component of the body's adaptive mechanisms to low oxygen conditions. In situations such as high altitudes, anemia, or respiratory disorders, where oxygen availability is compromised, the increased production of EPO enhances erythropoiesis, ensuring a continuous supply of mature red blood cells to improve the oxygen-carrying capacity of the blood. EPO production is finely tuned to maintain homeostasis. As oxygen levels normalize, the stimulus for EPO production diminishes, leading to a reduction in EPO synthesis. This negative feedback loop ensures that erythropoiesis is appropriately adjusted based on the body's oxygen needs, preventing excessive red blood cell production.[42]

Prevalence and Etiology of Anemia in HIV

Anemia is a prevalent and clinically significant complication in individuals living with Human Immunodeficiency Virus (HIV), contributing to a myriad of health challenges and impacting

overall well-being. The prevalence of anemia in HIV-infected individuals exceeds that of the general population, and understanding its etiology is crucial for effective management. The prevalence of anemia in individuals with HIV is a dynamic parameter that varies across different stages of the disease. Studies have reported a wide range, with estimates suggesting that up to 30% to 95% of individuals with HIV may experience anemia at some point during their disease course. The prevalence is influenced by factors such as the stage of HIV infection, the presence of comorbidities, and access to healthcare. HIV infection directly impacts the bone marrow, leading to impaired erythropoiesis. The virus can infect hematopoietic progenitor cells, disrupting the normal production of red blood cells. Additionally, inflammatory cytokines induced by HIV contribute to the inhibition of erythropoiesis. Opportunistic infections, common in individuals with advanced HIV disease and compromised immune systems, can directly or indirectly contribute to anemia. Pathogens such as Mycobacterium avium complex, cytomegalovirus (CMV), and Mycobacterium tuberculosis can impact erythropoiesis and exacerbate anemia.[44-61]

Antiretroviral therapy (ART) has revolutionized the management of HIV; however, certain medications, particularly zidovudine, used in some ART regimens, may cause bone marrow suppression and lead to anemia as a side effect. Persistent immune activation and chronic inflammation, hallmarks of HIV infection, contribute to the dysregulation of cytokines. Elevated levels of inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ), can suppress erythropoiesis and promote anemia. Malnutrition and deficiencies in essential nutrients, particularly iron, vitamin B12, and folate, can exacerbate anemia in individuals with HIV. These nutritional deficiencies may result from inadequate dietary intake, malabsorption, or altered metabolism associated with HIV infection. Anemia is not only a consequence of HIV infection but also a potential contributor to disease progression. Reduced oxygen-carrying capacity can exacerbate tissue hypoxia, impacting immune function and exacerbating existing comorbidities. Anemia has been associated with increased morbidity and mortality in individuals with HIV.[62-80]

Mechanisms Underlying HIV-Related Anemia

HIV-related anemia is a complex hematological manifestation influenced by a variety of interconnected mechanisms. The interplay between the virus, immune responses, and hematopoietic processes contributes to the development and progression of anemia in individuals living with HIV. Chronic HIV infection triggers the release of pro-inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ). Elevated levels of these cytokines disrupt the normal regulatory pathways of erythropoiesis in the bone marrow, leading to decreased red blood cell production. The bone marrow, crucial for red blood cell formation, becomes a target of HIV. Hematopoietic progenitor cells in the bone marrow can be directly infected by the virus, leading to their dysfunction and impaired ability to generate red blood cells. This direct impact on erythroid precursors contributes to bone marrow suppression. HIV infection induces chronic immune activation, leading to the production of antibodies and cytotoxic T cells. These immune responses, while attempting to control the virus, can inadvertently target and destroy red blood cells, contributing to hemolysis and anemia.[81-84]

Opportunistic infections commonly seen in advanced HIV disease, such as cytomegalovirus (CMV), can directly infect red blood cells or induce immune-mediated hemolysis, further reducing the lifespan of circulating erythrocytes. Inflammatory cytokines, particularly IL-6, stimulate the release of hepcidin, a key regulator of iron metabolism. Elevated levels of hepcidin lead to decreased iron absorption in the gastrointestinal tract and sequestration of iron in macrophages, resulting in functional iron deficiency and impaired erythropoiesis. Chronic inflammation and hemolysis associated with HIV-related anemia contribute to a shortened lifespan of red blood cells. The accelerated turnover of erythrocytes can outpace the ability of the reticuloendothelial system to recycle iron from senescent red blood cells, leading to a state of relative iron deficiency. Certain antiretroviral medications, particularly zidovudine, commonly used in HIV treatment regimens, can induce bone marrow suppression. The toxicity to hematopoietic progenitor cells may lead to a reduction in red blood cell production and exacerbate anemia.[85-90]

Erythropoietin Therapy: Risks and Benefits

Erythropoietin (EPO) therapy has been considered a viable intervention for managing anemia in various clinical contexts, including HIV infection. However, like any medical intervention, EPO therapy is associated with both potential risks and benefits. EPO, as a hematopoietic growth factor, stimulates the production of red blood cells in the bone marrow. The primary and anticipated benefit of EPO therapy is the elevation of hemoglobin levels, addressing the anemia associated with HIV infection. Improved hemoglobin levels contribute to enhanced oxygen-carrying capacity and may alleviate symptoms of anemia. By mitigating anemia-related symptoms such as fatigue, weakness, and dyspnea, EPO therapy has the potential to improve the overall quality of life for individuals living with HIV. Symptomatic relief can enhance daily functioning, mobility, and the ability to engage in regular activities. EPO therapy is associated with an increased risk of thromboembolic events, including deep vein thrombosis and pulmonary embolism. The stimulation of erythropoiesis can lead to a higher viscosity of the blood, predisposing individuals to clot formation.[91]

Elevated hemoglobin levels resulting from EPO therapy may contribute to increased blood viscosity and hypertension. Managing blood pressure becomes crucial in individuals receiving EPO to mitigate the risk of cardiovascular events. Although rare, the development of PRCA has been reported in individuals receiving EPO, particularly in those with chronic kidney disease. PRCA is characterized by a severe reduction in red blood cell production and may necessitate discontinuation of EPO therapy. EPO therapy can lead to increased iron utilization, and without proper iron supplementation and monitoring, individuals may be at risk of iron overload. Excess iron can contribute to oxidative stress and organ damage. Long-term EPO therapy may lead to the development of neutralizing antibodies, reducing the efficacy of EPO. This phenomenon can result in inadequate erythropoietic response and may necessitate dose adjustments or discontinuation of therapy. The risks and benefits of EPO therapy must be carefully weighed on an individual basis, considering factors such as the severity of anemia, underlying comorbidities, and the overall clinical status of the patient. Close monitoring and adherence to established guidelines are essential to minimize potential risks.[91]

Optimal Dosing Strategies

Erythropoietin (EPO) therapy, while holding promise in managing anemia in HIV-infected individuals, requires careful consideration of dosing strategies to balance therapeutic benefits with potential risks. Optimal dosing aims to achieve target hemoglobin levels effectively while minimizing adverse effects. Tailoring EPO dosing begins with a comprehensive assessment of the patient's baseline hemoglobin levels. Individual variations in anemia severity influence the starting dose, guiding clinicians in developing personalized treatment plans. Stratifying anemia severity based on hemoglobin levels helps establish appropriate dosing regimens. Mild, moderate, or severe anemia dictates the intensity of EPO therapy, with more conservative approaches for mild cases and escalated strategies for severe anemia. Evaluating renal function is essential as impaired kidney function can affect the clearance of EPO. Adjustments to the dosing regimen may be necessary in individuals with compromised renal function to prevent EPO accumulation and potential adverse effects. Individuals with pre-existing cardiovascular conditions require cautious dosing. Elevated hemoglobin levels from aggressive EPO therapy may increase the risk of thromboembolic events and hypertension. Monitoring cardiovascular health is crucial for dose optimization.[91]

Close monitoring of hemoglobin levels is fundamental to adjusting EPO doses. Regular assessments help gauge the individual's response to therapy and guide dose titration to achieve and maintain target hemoglobin concentrations. Implementing titration protocols involves adjusting EPO doses based on observed hemoglobin trends. A gradual approach minimizes the risk of overshooting target levels, allowing for a more controlled response and reducing the likelihood of adverse events. Assessing and maintaining adequate iron levels is integral to optimizing EPO therapy. Iron supplementation may be necessary, especially in individuals with concomitant iron deficiency or functional iron deficiency, to enhance the efficacy of EPO. Vigilant monitoring for iron overload is crucial, particularly in cases where EPO therapy leads to increased iron utilization. Regular assessments guide adjustments in iron supplementation to prevent excess iron accumulation and associated complications. Recognizing individual variations in response and tolerance is paramount. Factors such as age, overall health status, and concurrent medications influence how patients react to EPO therapy. A patient-centered approach ensures that dosing aligns with individual needs and tolerances. Following established guidelines for EPO therapy in HIV-related anemia is essential. Adhering to evidence-based recommendations ensures that dosing aligns with best practices, minimizing the risk of adverse events and optimizing therapeutic outcomes. Implementing safety protocols involves proactive management of potential risks associated with EPO therapy. Monitoring for adverse events, particularly thromboembolic events and hypertension, and promptly addressing any concerns contribute to the overall safety of the treatment.[90]

Clinical Outcomes of Erythropoietin Therapy in HIV

Erythropoietin (EPO) therapy, when employed in the management of anemia in individuals with Human Immunodeficiency Virus (HIV), yields diverse clinical outcomes that extend beyond hematological parameters. A primary clinical outcome of EPO therapy is the significant elevation

of hemoglobin levels. By stimulating erythropoiesis, EPO effectively addresses the underlying anemia associated with HIV infection. Studies consistently demonstrate a positive correlation between EPO administration and increased hemoglobin concentrations, thereby enhancing oxygen-carrying capacity. The individualized nature of patient responses necessitates careful monitoring and titration to achieve target hemoglobin levels. The success of EPO therapy in improving hemoglobin is contingent upon adherence to dosing strategies, ongoing assessments, and adjustments based on individual requirements. EPO therapy goes beyond the numerical improvement in hemoglobin levels; it translates into tangible symptomatic relief. Patients commonly report reductions in fatigue, weakness, and dyspnea, contributing to an enhanced overall quality of life.[92]

Beyond alleviating general fatigue, EPO-induced improvements in hemoglobin levels may lead to enhanced exercise tolerance. Individuals receiving EPO may experience increased stamina and physical well-being, fostering a more active and engaged lifestyle. EPO therapy has been associated with a decreased need for blood transfusions in individuals with HIV-related anemia. By addressing the underlying cause of anemia and promoting endogenous red blood cell production, EPO reduces reliance on exogenous blood products. The reduction in transfusion requirements not only minimizes the associated risks, including transfusion reactions and infections, but also contributes to healthcare cost-efficiency. EPO therapy, in this context, emerges as a strategic intervention with potential economic benefits. While some studies suggest a correlation between anemia and accelerated disease progression in HIV, the impact of EPO therapy on long-term HIV outcomes remains an area of ongoing investigation. The potential influence of EPO on disease progression requires further elucidation through well-designed longitudinal studies. The immunomodulatory effects of EPO, beyond its role in erythropoiesis, may contribute to broader impacts on the immune system. Exploring the potential interactions between EPO therapy and HIV pathogenesis remains an active area of research. Vigilant monitoring for thromboembolic events is imperative during EPO therapy. Clinicians must assess and manage factors contributing to increased thrombotic risk, such as elevated hemoglobin levels and pre-existing cardiovascular conditions. Proactive management of hypertension is essential, considering the potential for EPO-induced elevation in blood pressure. Antihypertensive measures may be required to mitigate cardiovascular risks associated with elevated hemoglobin levels. Adequate iron supplementation and monitoring are critical to prevent or address iron deficiency or overload. Optimizing iron status supports the efficacy of EPO therapy and minimizes associated complications.[92]

Conclusion

The physiological role of EPO as a regulator of erythropoiesis sets the foundation for understanding its therapeutic potential. The prevalence of anemia in individuals with HIV, influenced by factors ranging from viral effects to medication-induced bone marrow suppression, underscores the need for targeted interventions. EPO therapy, while holding promise in improving hemoglobin levels and alleviating anemia-associated symptoms, requires careful consideration of risks and benefits. The potential for thromboembolic events, hypertension, and other adverse effects necessitates a nuanced, patient-centered approach. Optimal dosing strategies, grounded in

individualized assessments, monitoring, and adherence to safety protocols, play a pivotal role in maximizing therapeutic benefits. The clinical outcomes of EPO therapy extend beyond hematological improvements, encompassing symptomatic relief, reductions in transfusion requirements, and potential impacts on disease progression.

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
8. Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. Int. J. Adv. Res. Biol. Sci. 2015;2(7):58-62.
9. Obeagu EI, Okoroiwu II, Ezimah AC. Evaluation of serum erythropoietin levels in chronic kidney disease patients in Federal Medical centre, Umuahia, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(4):15-21.
10. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
11. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8.
12. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.

13. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
14. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
15. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
16. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
17. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
18. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
19. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
20. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
21. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
22. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.

23. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
24. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
25. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
26. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
27. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
28. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
29. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
30. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
31. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
32. Obeagu EI, Obeagu GU, Nchuma BO, Amazue PO. A Review on erythropoietin receptor (EpoR). Int. J. Adv. Res. Biol. Sci. 2015;2(8):80-4.
33. Obeagu EI. Erythrocyte enumeration and serum erythropoietin in chronic kidney disease patients: A study in Federal Medical Centre, Umuahia, Nigeria. International Journal of Advanced Research in Biological Sciences. 2016;3(7):163-70.
34. Ifeanyi OE. A review on erythropoietin. Int J Adv Res Biol Sci. 2015;2(4):35-47.

35. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
36. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4.
37. Obeagu EI, Okoroiwu IL, Obeagu GU. Relationship between Thrombopoietin and Interleukin 3: A Review. Int J Curr Res Chem Pharm. Sci. 2022;9(1):7-13.
38. Obeagu EI, Obeagu GU, Amilo GI. Haematological changes in patients of chronic kidney disease in Umuahia, Abia State, Nigeria. Curr Trends Biomed Eng Biosci. 2018; 11:34-7.
39. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. Int. J. Curr. Res. Med. Sci. 2018;4(10):42-8.
40. Obeagu EI. Blood Transfusion: A Powerful Process of Saving Anaemic Patients. EC Emergency Medicine and Critical Care. 2020;4(7):33-40.
41. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
42. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
43. Jelkmann W. Erythropoietin. Sports Endocrinology. 2016; 47:115-127.
44. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
45. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
46. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
47. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
48. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria

Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.

49. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
50. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
51. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
52. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
53. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
54. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
55. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
56. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
57. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568

58. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
59. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
60. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
61. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
62. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
63. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
64. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
65. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
66. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-67.
67. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
68. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%2

0Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.

69. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
70. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
71. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
72. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
73. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
74. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
75. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
76. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
77. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
78. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
79. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
80. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
81. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.

82. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
83. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
84. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
85. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
86. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
87. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
88. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
89. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
90. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
91. Murua A, Orive G, Hernández RM, Pedraz JL. Emerging technologies in the delivery of erythropoietin for therapeutics. Medicinal Research Reviews. 2011;31(2):284-309.
92. Kimel M, Leidy NK, Mannix S, Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value in Health. 2008;11(1):57-75.